Nektar Therapeutics (NKTR)

16.99
NASDAQ : Health Technology
Prev Close 16.98
Day Low/High 16.58 / 17.27
52 Wk Low/High 16.56 / 69.76
Avg Volume 2.21M
Exchange NASDAQ
Shares Outstanding 175.27M
Market Cap 2.98B
EPS 4.00
P/E Ratio N/A
Div & Yield N.A. (N.A)
Get Ready for Nektar Therapeutics (NKTR) Stock to Break Out

Get Ready for Nektar Therapeutics (NKTR) Stock to Break Out

A rally to $19 could ensue for Nektar (NKTR) shares.

First Week of December 18th Options Trading For Nektar Therapeutics (NKTR)

First Week of December 18th Options Trading For Nektar Therapeutics (NKTR)

Investors in Nektar Therapeutics saw new options become available this week, for the December 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NKTR options chain for the new December 18th contracts and identified one put and one call contract of particular interest.

Nektar Therapeutics (NKTR) Marked As A Dead Cat Bounce Stock

Nektar Therapeutics (NKTR) Marked As A Dead Cat Bounce Stock

Trade-Ideas LLC identified Nektar Therapeutics (NKTR) as a "dead cat bounce" (down big yesterday but up big today) candidate

NKTR Makes Bullish Cross Above Critical Moving Average

NKTR Makes Bullish Cross Above Critical Moving Average

In trading on Tuesday, shares of Nektar Therapeutics crossed above their 200 day moving average of $12.69, changing hands as high as $12.98 per share. Nektar Therapeutics shares are currently trading up about 1.6% on the day.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABTL, EFOI, IFT, JMBA, MRVC Downgrades: AAME, ASC, BCR, CCIH, CFX, CHS, CRAY, CRTN, EQT, EVRI, GE, GENC, MNK, MYE, NKTR, PFLT, PHH, RGS, SLG, STBZ, WABC, WAIR Initiations: BHBK, IMDZ, MTBC, NAME, NVCN, PFNX, TPUB, TSQ, XENT Read on to get TheStreet Quant Ratings' detailed report:

Nektar Therapeutics (NKTR) Stock: Weak On High Volume Today

Nektar Therapeutics (NKTR) Stock: Weak On High Volume Today

Trade-Ideas LLC identified Nektar Therapeutics (NKTR) as a weak on high relative volume candidate

First Week of February 2016 Options Trading For Nektar Therapeutics (NKTR)

First Week of February 2016 Options Trading For Nektar Therapeutics (NKTR)

Investors in Nektar Therapeutics saw new options begin trading this week, for the February 2016 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Today's Weak On High Volume Stock: Nektar Therapeutics (NKTR)

Today's Weak On High Volume Stock: Nektar Therapeutics (NKTR)

Trade-Ideas LLC identified Nektar Therapeutics (NKTR) as a weak on high relative volume candidate

Today's Perilous Reversal Stock: Nektar Therapeutics (NKTR)

Today's Perilous Reversal Stock: Nektar Therapeutics (NKTR)

Trade-Ideas LLC identified Nektar Therapeutics (NKTR) as a "perilous reversal" (up big yesterday but down big today) candidate

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BZH, CAMT, CLR, DIN, EMN, HFBC, NKTR, POL, RDS.A, TMUS, WWWW Downgrades: ANH, BDC, CLD, CTCT, CWEI, GLRE, GOV, HBIO, LNG, MINI, MNR, NCR, ORN, PDLI, PEBO, TKR, VIA, VIAB Initiations: AAC Read on to get TheStreet Quant Ratings' detailed report:

Nektar Therapeutics (NKTR) Is Today's Dead Cat Bounce Stock

Nektar Therapeutics (NKTR) Is Today's Dead Cat Bounce Stock

Trade-Ideas LLC identified Nektar Therapeutics (NKTR) as a "dead cat bounce" (down big yesterday but up big today) candidate

First Week of NKTR June 19th Options Trading

First Week of NKTR June 19th Options Trading

Investors in Nektar Therapeutics saw new options begin trading this week, for the June 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NKTR options chain for the new June 19th contracts and identified one put and one call contract of particular interest.

Interesting NKTR Put And Call Options For November 20th

Interesting NKTR Put And Call Options For November 20th

Investors in Nektar Therapeutics saw new options begin trading this week, for the November 20th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Trade-Ideas: Nektar Therapeutics (NKTR) Is Today's Weak On High Relative Volume Stock

Trade-Ideas: Nektar Therapeutics (NKTR) Is Today's Weak On High Relative Volume Stock

Trade-Ideas LLC identified Nektar Therapeutics (NKTR) as a weak on high relative volume candidate

Nektar Therapeutics (NKTR) Stock Tanks Today on Failed Phase III Breast Cancer Treatment Results

Nektar Therapeutics (NKTR) Stock Tanks Today on Failed Phase III Breast Cancer Treatment Results

Nektar Therapeutics (NKTR) shares are down double digits after the company reported statistically insignificant phase III BEACON results for its breast cancer treatment candidate.

Nektar Therapeutics (NKTR): Heavy Pre-Market Activity

Nektar Therapeutics (NKTR): Heavy Pre-Market Activity

Trade-Ideas LLC identified Nektar Therapeutics (NKTR) as a pre-market mover with heavy volume candidate

Fly Watch: Nektar Therapeutics Breast Cancer Data Expected Soon

Fly Watch: Nektar Therapeutics Breast Cancer Data Expected Soon

The risk/reward ratio for shares of Nektar Therapeutics is "potentially interesting" heading into a data readout from a trial of its breast cancer treatment, JPMorgan stated.

First Week of March 20th Options Trading For Nektar Therapeutics (NKTR)

First Week of March 20th Options Trading For Nektar Therapeutics (NKTR)

Investors in Nektar Therapeutics saw new options become available this week, for the March 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NKTR options chain for the new March 20th contracts and identified one put and one call contract of particular interest.

Interesting NKTR Put And Call Options For August 2015

Interesting NKTR Put And Call Options For August 2015

Investors in Nektar Therapeutics saw new options begin trading this week, for the August 2015 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Nektar Therapeutics (NKTR) Weak On High Volume Today

Nektar Therapeutics (NKTR) Weak On High Volume Today

Trade-Ideas LLC identified Nektar Therapeutics (NKTR) as a weak on high relative volume candidate

How Will AstraZeneca (AZN) Stock React to FDA's Movantik Approval?

How Will AstraZeneca (AZN) Stock React to FDA's Movantik Approval?

Shares of AstraZeneca (AZN) fell in afternoon trading Tuesday despite the FDA's approval of the constipation drug Movantik, developed by AstraZeneca and and Nektar Therapeutics (NKTR).

Notable Two Hundred Day Moving Average Cross - NKTR

Notable Two Hundred Day Moving Average Cross - NKTR

In trading on Tuesday, shares of Nektar Therapeutics crossed below their 200 day moving average of $11.96, changing hands as low as $11.92 per share. Nektar Therapeutics shares are currently trading down about 2.7% on the day.

First Week of February 2015 Options Trading For Nektar Therapeutics (NKTR)

First Week of February 2015 Options Trading For Nektar Therapeutics (NKTR)

Investors in Nektar Therapeutics saw new options begin trading this week, for the February 2015 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

3 Stocks Driving The Drugs Industry Higher

3 Stocks Driving The Drugs Industry Higher

TheStreet highlights 3 stocks pushing the drugs industry higher today.

First Week of July 19th Options Trading For Nektar Therapeutics (NKTR)

First Week of July 19th Options Trading For Nektar Therapeutics (NKTR)

Investors in Nektar Therapeutics saw new options become available this week, for the July 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NKTR options chain for the new July 19th contracts and identified one put and one call contract of particular interest.

Why Nektar Therapeutics (NKTR) Stock Is Up Today

Why Nektar Therapeutics (NKTR) Stock Is Up Today

Nektar Therapeutics (NKTR) stock continues to climb following a 'buy' rating by analysts at Jefferies (JEF)

MannKind Rival, Also Developing Inhaled Insulin Device, Files $75M IPO

MannKind Rival, Also Developing Inhaled Insulin Device, Files $75M IPO

Dance Biopharma is developing a device which sends vaporized insulin liquid into a patient's lungs.

First Week of April 19th Options Trading For Nektar Therapeutics (NKTR)

First Week of April 19th Options Trading For Nektar Therapeutics (NKTR)

Investors in Nektar Therapeutics saw new options become available this week, for the April 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NKTR options chain for the new April 19th contracts and identified one put and one call contract of particular interest.

Use Options For A Chance To Buy NKTR At A 42% Discount

Use Options For A Chance To Buy NKTR At A 42% Discount

Looking back to 33 days ago, Nektar Therapeutics priced a 8,500,000 share secondary stock offering at $12.75 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over the course of time and based on early trading on Monday, the stock is now 6.7% above the offering price.

Nektar Therapeutics (NKTR) Is Today's Pre-Market Mover With Heavy Volume Stock

Nektar Therapeutics (NKTR) Is Today's Pre-Market Mover With Heavy Volume Stock

Trade-Ideas LLC identified Nektar Therapeutics (NKTR) as a pre-market mover with heavy volume candidate

TheStreet Quant Rating: D (Sell)